Who are CASI Pharmaceuticals, Inc.'s main suppliers?

CASI Pharmaceuticals, Inc. (CASI) key suppliers include: BIOINVENT, ALESTA-THERAPEUTICS-B-V, BLACK-BELT-TX-LTD, GUANGZHOU-GLORIA-BIOSCIENCES-CO-LTD. View the full supplier network at chainsifter.com/chain/CASI.

Who are CASI Pharmaceuticals, Inc.'s major customers?

CASI Pharmaceuticals, Inc. (CASI) key customers include: CNMC, CRPCGIT, Johnson & Johnson, Johnson & Johnson, BEIJING-TECH-CO-LTD and 20 more. View the full customer network at chainsifter.com/chain/CASI.

What sector is CASI Pharmaceuticals, Inc. in?

CASI Pharmaceuticals, Inc. (CASI) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CASI Pharmaceuticals, Inc. Supplier List (CASI): 4 Verified Suppliers

4Suppliers

25Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

CASI Pharmaceuticals, Inc. (CASI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

32Total relationships

1Distinct source URLs

9High confidence

0.699Average confidence

2026-09-14Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

CASI Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
BIOINVENT	BIOINVENT	90%	As an import drug product into China, we expect that future supply of BI-1206 will be met by our partner BioInvent and its contract manufacturers.
ALESTA-THERAPEUTICS-B-V	ALESTA-THERAPEUTICS-B-V	85%	The Company expects that its clinical materials and commercial inventory will be supplied by one or more contract manufacturers with whom the Company has contracted with.
BLACK-BELT-TX-LTD	BLACK-BELT-TX-LTD	85%	The Company expects that its clinical materials and commercial inventory will be supplied by one or more contract manufacturers with whom the Company has contracted with.
GUANGZHOU-GLORIA-BIOSCIENCES-CO-LTD	GUANGZHOU-GLORIA-BIOSCIENCES-CO-LTD	80%	YuTuo® (zimberelimab injection) is distributed in China pursuant to a three-year distribution agreement we entered into with Guangzhou Gloria Biosciences Co., Ltd. in 2025, under which CASI China was…

CASI Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
CNMC	CNMC	90%	we established a business relationship with a sole distributor CNMC for the in-licensed product FOLOTYN®.
CRPCGIT	CRPCGIT	90%	we have a long-standing business relationship with our sole distributor CRPCGIT for the in-licensed product EVOMELA®.
JNJ	Johnson & Johnson	72%	. Mr. Su has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investmen…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from CASI graph: . Mr. Su has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-scien…
BEIJING-TECH-CO-LTD	BEIJING-TECH-CO-LTD	62%	ribution right of the products in China, and Riemser will be responsible for manufacturing and supplying CASI with clinical materials and commercial inventory. The Company is applying for generic reg…
BISON-CAPITAL-ACQUISITION-CORPORATION	BISON-CAPITAL-ACQUISITION-CORPORATION	62%	. Mr. Su has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investmen…
BLACK-BELT-THERAPEUTICS-LIMITED	BLACK-BELT-THERAPEUTICS-LIMITED	62%	related party, short term borrowings and current portion of long term borrowing. As of December 31, 2025 and December 31, 2024, the carrying amount of cash and cash equivalents, accounts receivable, …
CASI-PHARMACEUTICALS-CO-LTD	CASI-PHARMACEUTICALS-CO-LTD	62%	ribution right of the products in China, and Riemser will be responsible for manufacturing and supplying CASI with clinical materials and commercial inventory. The Company is applying for generic reg…
CLEAVE-THERAPEUTICS-INC	CLEAVE-THERAPEUTICS-INC	62%	obtained 14.1 % equity interest in Alesta Tx in exchange for its 14.1 % equity interest in Black Belt Tx. In July 2021, a new investor contributed 750,000 euros to Alesta Tx in exchange for 770,270 n…
EMERGING-TECHNOLOGY-PARTERNS-LLC	EMERGING-TECHNOLOGY-PARTERNS-LLC	62%	y involving the personal dishonesty or moral turpitude, and material breach of obligations under the employment agreement. The employment may also be terminated without cause upon 30-days advance wri…
EMERGING-TECHNOLOGY-PARTNERS-LLC	EMERGING-TECHNOLOGY-PARTNERS-LLC	62%	y involving the personal dishonesty or moral turpitude, and material breach of obligations under the employment agreement. The employment may also be terminated without cause upon 30-days advance wri…
GUANGZHOU-REDHILL-CAPITAL-INVESTMENT-MANAGEMENT-	GUANGZHOU-REDHILL-CAPITAL-INVESTMENT-MANAGEMENT-	62%	. Mr. Su has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investmen…
HAINAN-CO-LTD	HAINAN-CO-LTD	62%	ribution right of the products in China, and Riemser will be responsible for manufacturing and supplying CASI with clinical materials and commercial inventory. The Company is applying for generic reg…
HISANAGA-SEISAKUSHO-CO-LTD	HISANAGA-SEISAKUSHO-CO-LTD	62%	. Mr. Su has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investmen…
HLIO	Helios Technologies, Inc.	62%	Reciprocal relationship from HLIO graph: Reciprocal relationship from CASI graph: arketing authorization holder. Product Manufacturing 53 Table of Contents For the registration of locally manufacture…
HUMAN-LONGEVITY-INC	HUMAN-LONGEVITY-INC	62%	arketing authorization holder. Product Manufacturing 53 Table of Contents For the registration of locally manufactured drugs, the drug products need to be manufactured in China through either a self-…
KAIXIN-PHARMACEUTICALS-INC	KAIXIN-PHARMACEUTICALS-INC	62%	arketing authorization holder. Product Manufacturing 53 Table of Contents For the registration of locally manufactured drugs, the drug products need to be manufactured in China through either a self-…
KXIN	Kaixin Holdings	62%	Reciprocal relationship from KXIN graph: Reciprocal relationship from CASI graph: arketing authorization holder. Product Manufacturing 53 Table of Contents For the registration of locally manufacture…
OPTIVEST-CANADA-LTD	OPTIVEST-CANADA-LTD	62%	. Mr. Su has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investmen…
OPTIVEST-SYSTEMS-LTD	OPTIVEST-SYSTEMS-LTD	62%	. Mr. Su has extensive experiences in the bioscience industry, and he has been a well-known investor in the life-science industry. Mr. Su is currently a partner of Guangzhou Redhill Capital Investmen…
PANACEA-INNOVATION-LIMITED	PANACEA-INNOVATION-LIMITED	62%	related party, short term borrowings and current portion of long term borrowing. As of December 31, 2025 and December 31, 2024, the carrying amount of cash and cash equivalents, accounts receivable, …
PANACEA-VENTURE-HEALTHCARE-FUND-II-GP-COMPANY-LT	PANACEA-VENTURE-HEALTHCARE-FUND-II-GP-COMPANY-LT	62%	related party, short term borrowings and current portion of long term borrowing. As of December 31, 2025 and December 31, 2024, the carrying amount of cash and cash equivalents, accounts receivable, …
RIEMSER-PHARMA-GMBH	RIEMSER-PHARMA-GMBH	62%	es of BI-1206. Because BI-1206 underlying the acquired rights has not reached technological feasibility and has no alternative future uses, the Company expensed $ 5.9 million as acquired in-process r…
SINOPHARM-GROUP-TIANJIN-CO-LTD	SINOPHARM-GROUP-TIANJIN-CO-LTD	62%	f high credit quality and continually monitors the credit worthiness of these financial institutions The Company believes it is not exposed to significant credit risk on cash and cash equivalents. Ve…
SPECTRUM-PHARMACEUTICALS-INC	SPECTRUM-PHARMACEUTICALS-INC	62%	arketing authorization holder. Product Manufacturing 53 Table of Contents For the registration of locally manufactured drugs, the drug products need to be manufactured in China through either a self-…

CASI Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CASI-DEBT-8486	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
CASI-DEBT	Debt stack $18.9M	90%	Market cache reports total debt of $18.9M.

CASI Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for CASI Pharmaceuticals, Inc..

CASI Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
CASI-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 2 tracked holders.

CASI Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ABBV	AbbVie Inc.	100.00	2
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
CLGN	CollPlant Biotechnologies Ltd.	100.00	2
ADGM	Adagio Medical Holdings, Inc.	100.00	2
ACIU	AC Immune SA	100.00	2
ATON	AlphaTON Capital Corp	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
AURA	Aura Biosciences, Inc.	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
AORT	Artivion, Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
SNNUF	Smith & Nephew plc	100.00	2
ALC	Alcon Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
CRIS	Curis, Inc.	100.00	2

CASI Pharmaceuticals, Inc. Supply Chain